The End of the US Hemp Industry is Near - Closing the Delta-8 and Delta-9 Farm Bill Loophole Will End Hemp in America

end of hemp in america

The 2018 Farm Bill legalized the cultivation of hemp, distinguishing it from marijuana based on its low THC content. However, an emerging loophole has allowed the proliferation of psychoactive hemp-derived products, particularly delta-8 THC, which has led to significant regulatory and public health concerns. In response, a proposed amendment to the Farm Bill seeks to address these issues by banning hemp-derived cannabinoid products, including delta-8 THC. This proposed amendment, filed by Rep. Mary Miller (R-IL), aims to redefine hemp and close the existing loophole around intoxicating hemp. The amendment has sparked a heated debate among industry stakeholders, regulators, and lawmakers.

If you have followed the legal hemp market over the past 8 years and attended shows like the Benzinga Cannabis Conference, you know that the only thing keeping the US hemp industry alive, and on life-support at best, is the sale of commerical retail products that create revenue, ie, Delta-8 THC and Delta-9 THC products derived from hemp. While hemp-crete and hemp twine are nice stories, the only "cash crop" hemp has right now is selling "hemp that gets you high" to Americans that don't have acccess to legal weed.

As mentioned by a few VCs and investment firms at the industry trade shows, the only think keeping hemp alive in America is Delta-8 and Delta-9 THC products and sales.

That "loophole" in the original 2018 Farm Bill may be closing, and for good, with a new amendment put forward this week.

Key Provisions of the Proposed Amendment

The amendment includes several critical provisions designed to tighten regulations on hemp-derived products:

Redefinition of Hemp: Redefines hemp to exclude products containing detectable levels of THC and cannabinoids synthesized outside the plant.
Ban on Delta-8 THC: Explicitly bans hemp-derived products that contain psychoactive cannabinoids, such as delta-8 THC.
Enhanced Regulatory Oversight: Aims to provide clearer guidelines and stricter controls over the production and sale of hemp-derived products.

Concerns Leading to the Amendment

Proponents of the amendment argue that the current lack of regulation has led to several issues:

Marketing to Children and Teens: Psychoactive hemp products are often marketed in colorful packaging, resembling candy and snacks, raising concerns about their appeal to children and teenagers.
Unregulated Market: The proliferation of hemp-derived cannabinoids has resulted in an unregulated market where the safety and quality of products are inconsistent.
Public Health Risks: There are concerns about the potential health risks associated with the unregulated sale and consumption of these products.

Industry Opposition and Concerns

Industry stakeholders and advocates for the hemp industry have voiced strong opposition to the proposed amendment. Their main arguments include:

Impact on CBD Products: The amendment could criminalize many non-intoxicating CBD products that naturally contain trace amounts of THC.
Economic Consequences: The ban could devastate the hemp industry, resulting in significant job losses and economic decline.
Access to Health Products: Many Americans rely on hemp-derived products for health and wellness, and the ban could deny them access to these beneficial products.

Economic Implications

The hemp market is currently valued at approximately $28 billion, with a significant portion of this market driven by hemp-derived cannabinoid products. The proposed amendment could have profound economic implications, including:

Job Losses: Potential loss of tens of thousands of jobs in agriculture, retail, and manufacturing sectors.
Market Decline: A potential decline in sales and overall market value as many products would no longer be legally available.
Investment Uncertainty: Increased regulatory uncertainty could deter future investments in the hemp industry.

Regulatory Challenges

The hemp industry has faced numerous regulatory challenges since the legalization of hemp in 2018. Key regulatory hurdles include:

Lack of FDA Regulation: The FDA has yet to establish clear regulations for hemp-derived CBD products, creating a patchwork of state-level regulations and contributing to market instability.

Safety and Quality Standards: The absence of federal guidelines has led to inconsistent safety and quality standards across the industry.
Youth Access: The unregulated sale of psychoactive hemp products has raised concerns about youth access and potential misuse.

Legislative Process and Potential Outcomes

The amendment’s approval by the House Agriculture Committee is the first step in a potentially contentious legislative process. The Senate, which has yet to release its version of the Farm Bill, will play a crucial role in determining the amendment’s fate. Key considerations include:

Senate’s Stance: The Democratic-controlled Senate may take a different approach to the regulation of hemp-derived cannabinoids, potentially leading to a conflict between the two chambers.
Bipartisan Negotiations: Successful passage of the amendment will likely require bipartisan support and negotiations to reconcile differing viewpoints.
Final Legislation: The final version of the Farm Bill will need to balance the interests of public health, industry stakeholders, and regulatory clarity.

Broader Implications for Cannabinoid Regulation

The proposed amendment raises broader questions about the regulation of cannabinoids in general:

Defining Cannabinoids: The amendment’s language excluding detectable levels of THC and synthesized cannabinoids could impact the regulation of other cannabinoids, such as CBD.
Regulatory Parity: Proponents argue that the amendment would create regulatory parity and facilitate state-level regulation of intoxicating hemp products.
Future of Cannabinoid Products: The regulation of cannabinoids will continue to evolve, with ongoing debates about the safety, efficacy, and legality of various products.

Public Health Considerations

The shift towards greater regulation of hemp-derived cannabinoids has significant public health implications:

Consumer Safety: Enhanced regulatory oversight could improve consumer safety by ensuring that hemp-derived products meet consistent quality and safety standards.
Health Risks: The unregulated sale of psychoactive hemp products poses potential health risks, particularly for vulnerable populations.
Research and Education: Increased research and public education efforts are needed to fully understand the health impacts of hemp-derived cannabinoids and inform regulatory policies.

Industry Adaptation and Future Outlook

The hemp industry will need to adapt to the proposed regulatory changes if the amendment is enacted. Key strategies for adaptation include:

Compliance and Certification: Producers and manufacturers will need to invest in compliance and certification processes to meet new regulatory standards.
Product Innovation: The industry may shift focus towards non-psychoactive hemp applications and develop new products that comply with stricter regulations.
Advocacy and Engagement: Ongoing advocacy and engagement with policymakers will be essential to ensure that the industry's interests are represented in regulatory discussions.

Conclusion

The proposed Farm Bill amendment to ban hemp-derived cannabinoid products represents a significant shift in U.S. agricultural and regulatory policy. While proponents argue that it addresses critical public health and safety concerns, industry stakeholders warn of devastating economic consequences and the potential loss of beneficial products. As the amendment moves through the legislative process, the hemp industry faces a period of uncertainty and adaptation. The outcome of this debate will shape the future of hemp regulation, balancing the need for consumer protection with the growth and innovation of a burgeoning industry.